Fresh Valuation Checks Across Key Stocks

A series of new Simply Wall St and MarketBeat updates on 4 April 2026 highlight how differing valuation methods are shaping views on companies across autos, software, IT solutions, biotech and payments. Discounted cash flow, price‑to‑earnings, price‑to‑book and excess‑returns models yield mixed messages, particularly where recent share price moves have been sharp.

Several names, including CarMax, Paycom Software, CDW and Mastercard (MA), are framed as trading below internally calculated fair value on at least one model, while biotech names such as CRISPR Therapeutics and Protagonist Therapeutics are assessed primarily through balance‑sheet and cash‑flow lenses given their stage of development.

CarMax shares trade around US$41 and have fallen 45.5% over the past year, despite gains of 4.9% year to date. Recent performance shows a 0.9% move over the last week and a 2.0% decline over 30 days, underlining mixed momentum for the used vehicle retailer.

A Simply Wall St DCF model, using a 2‑stage free cash flow to equity approach and latest twelve‑month free cash flow of about US$2.01 billion, estimates intrinsic value at US$66.38 per share. That implies CarMax trades at about a 37.9% discount, generating a valuation score of 5 out of 6 and an "UNDERVALUED" label on this framework.

On earnings metrics, CarMax’s P/E of 12.77x sits below the Specialty Retail industry average of 18.78x and a peer average of 21.30x. A proprietary Fair Ratio of 18.31x again suggests undervaluation. Separately, MarketBeat reports the stock opened at US$41.21, with a market cap of US$5.84 billion, P/E of 13.60, PEG of 1.05 and beta of 1.30.

Wall Street Zen has upgraded CarMax from "sell" to "hold". Across the broader analyst community, MarketBeat cites one Strong Buy, one Buy, twelve Hold and five Sell ratings, for a consensus "Reduce" stance and an average price target of US$39.71.

Paycom Software recently closed at US$123.56 after a 5.6% gain over seven days, 9.6% over 30 days, 18.9% year to date and 37.1% over one year. Over three and five years, shareholders have seen returns of 56.3% and 66.8% respectively.

A DCF analysis using a 2‑stage free cash flow to equity model and latest free cash flow of about US$434.9 million arrives at intrinsic value of roughly US$304.40 per share, implying the stock is 59.4% below this estimate and earning a valuation score of 5 out of 6. Paycom trades on a P/E of 14.49x, below the Professional Services industry average of 19.31x and a peer average of 17.75x. A Fair Ratio of 18.84x again points to "UNDERVALUED" status.

CDW shows a similar pattern. The shares recently closed at US$122.01, with returns of 3.2% over the last week, a 1.9% decline over 30 days, and year‑to‑date and one‑year declines of 8.4% and 14.1%. Three‑ and five‑year returns are down 31.5% and 26.0%.

Using a DCF model based on trailing free cash flow of about US$1.07 billion and projections such as US$1.24 billion in 2027, Simply Wall St estimates intrinsic value at US$149.61, an 18.4% discount to the recent price. CDW carries a valuation score of 5 out of 6 and trades on a P/E of 14.6x, below an Electronic industry average of 29.4x and a peer average of 17.5x. A Fair Ratio of 23.0x results in another "UNDERVALUED" assessment.

CRISPR Therapeutics trades around US$49.51 after a 1‑day gain of 1.43% and a 7‑day return of 8.22%, offset by a 30‑day decline of 13.64% and a three‑month fall of about 7.9%. The one‑year total shareholder return is 51.64%, but longer‑term outcomes are described as weaker.

With limited current revenue of US$3.51 million and a net loss of US$581.6 million, valuation focuses on its balance sheet. CRISPR trades on a price‑to‑book ratio of 2.5x, above the broader U.S. biotech industry average of 2.2x, but below a narrower peer group average of 9.2x. Simply Wall St judges the P/B level as "ABOUT RIGHT" while highlighting risks tied to complex, highly regulated gene‑editing therapies.

Protagonist Therapeutics’ valuation is examined through discounted cash flow and P/B. A DCF model using latest twelve‑month free cash flow of about US$57.37 million and projections rising to US$624 million by 2030 suggests intrinsic value of about US$366.45 per share, versus a recent price near US$103.78, implying a 71.7% discount and a valuation score of 3 out of 6.

On a P/B basis, Protagonist trades at about 10.77x, above the Biotech industry average of 2.24x but below a peer average around 19.80x. A Fair Ratio points to the shares being "ABOUT RIGHT" on this metric. The stock’s performance includes gains of 4.9% over seven days, 13.5% over 30 days, 19.0% year to date, 133.5% over one year and roughly five‑fold over three years.

For Mastercard (MA), an Excess Returns model integrating book value, stable EPS and cost of equity estimates arrives at intrinsic value of about US$642.70 per share, 23.2% above a current price near US$493. That leads Simply Wall St to describe the stock as undervalued on this framework, with a valuation score of 3 out of 6.

Recent Mastercard share performance shows a 1.9% move over seven days, a 6.0% decline over 30 days, a 12.4% decline year to date, a 1.3% gain over one year, and three‑ and five‑year returns of 38.7% and 33.4%. On earnings, however, the stock trades at about 29.40x P/E, above a Diversified Financial industry average of 15.39x and a peer average of 17.94x. A Fair Ratio of 19.93x leads to an "OVERVALUED" conclusion on this metric.

In large‑cap pharma, Bristol Myers Squibb (BMY)’s recent focus has been on pipeline updates. In late March 2026, it reported that its Phase 3 SCOUT‑HCM trial of Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy met its primary endpoint over 28 weeks, with clinically meaningful and statistically significant reductions in Valsalva LVOT gradient and supportive safety data versus placebo.

The data, presented at the American College of Cardiology 2026 meeting and published in The New England Journal of Medicine, highlight the potential to extend Camzyos beyond its current adult indication. Bristol Myers (BMY) also advanced an expanded collaboration with Janux Therapeutics, triggering a US$35 million milestone payment tied to a tumor‑activated therapeutic candidate. Analyst narratives referenced by Simply Wall St project Bristol Myers (BMY)’ revenue of US$41.3 billion and earnings of US$9.2 billion by 2028 under one scenario, with some other analysts modeling revenue declines to roughly US$37.5 billion by 2029.